Sellas Life Sciences Revamps Executive Pay as a Leukemia Trial Nears Its Defining Moment

Sellas Life Sciences reports 78 of 80 patient deaths in phase 3 AML trial, fueling stock volatility and acquisition speculation after executive severance amendments.

The final toll is almost there, but nobody can see it yet. Sellas Life Sciences has recorded 78 of the 80 patient deaths needed to unlock the survival data from its phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia. That gap of just two missing events has turned the stock into one of the most volatile names on the market, with an annualized 30-day volatility exceeding 127%. Yet the company is not simply waiting in silence — it has been quietly tightening its corporate armor.

In recent weeks, Sellas overhauled the severance packages for its top executives. CEO Angelos Stergiou’s new contract calls for a lump-sum change-of-control payment, while CFO John Burns and Chief Development Officer Dragan Cicic would each receive 15 months of base salary, target bonuses, COBRA reimbursements and full acceleration of their stock options if a takeover occurs. The timing of these amendments, coinciding with the final stretch of a pivotal registration study, has prompted some analysts to speculate that the board may be preparing for an acquisition — though no formal talks have been confirmed.

The market itself is already pricing in a binary outcome. On Friday, shares closed at €11.30, down 4.64% on the day and 12.06% for the week. That retreat from the 52-week high of €15.25, touched on June 30, represents a loss of roughly a quarter of the stock’s value. Even so, the equity remains up 82.26% over the past 30 days and a stunning 597.53% year-over-year. Against the 52-week low of €1.22 from November 2025, the gain stretches to 824.71%.

The core of the suspense lies in the interpretation of the delay. With 78 events in the bag, the longer the 79th and 80th take to materialize, the more speculation swirls that patients on the control arm — the best available therapy — may be living longer than expected. Stergiou has publicly backed that optimistic read, pushing back against suggestions that new treatment options could be artificially extending survival in the control group. He points out that there is no approved maintenance therapy for second complete remission in AML, a fact that weakens the counterargument.

Not everyone buys that narrative. Skeptics view the missing two events as mere noise until the data are unblinded. No amount of inference replaces an actual Kaplan-Meier curve, they argue, and the stock’s violent swings reflect a tug-of-war between anticipation and impatience rather than any fundamental shift. That tension, not a hard number, is driving the daily volatility that has made Sellas a favorite of retail traders.

The bull case, however, has some firm supports. On July 6, James Molloy of Alliance Global raised his price target on Sellas to $25 from $10 and reiterated a buy rating, arguing that the wait for the final two events could itself be a bullish signal. The consensus analyst target stands at €15.33, roughly 35.6% above Friday’s closing price. Financially, the company is on solid footing for now: it held $107.1 million in cash and equivalents as of March 31, with an additional $7.5 million flowing in during the second quarter from warrant exercises. That runway should cover operations through the data readout without an immediate capital raise.

Still, the bear case is just as concrete. A large chunk of the recent rally originated not from clinical breakthroughs but from social-media momentum that propelled the stock into the mid-teens in late June before it snapped back just as quickly — with no new trial results or partnership announcements to justify the move. Such speculative energy can dissipate as fast as it appears. Meanwhile, the company burns cash with no revenue, and a $150 million at-the-market offering facility hangs over the stock, ready to dilute existing holders at any time. If the unblinded REGAL data disappoint, the combination of an already stretched valuation, thin float and dilution risk could push the stock well below its 50-day moving average of €7.81.

Institutional positioning offers a mixed picture. MassMutual Private Wealth & Trust reported holding a mere 24 shares worth about $354 as of June 30 — a token position that nonetheless gets noticed amid the heightened attention. CoreCap Advisors built a new 690-share stake worth roughly $10,180, while Gamma Investing cut its holding by 32% to 556 shares. First Financial Bank kept a more substantial commitment of 10,000 shares valued at $147,600.

A separate catalyst could emerge from an unrelated pipeline asset. Sellas began recruiting for a phase 2 study of SLS009 in newly diagnosed AML patients in March, with topline data expected in the fourth quarter of this year. If the REGAL readout proves ambiguous, those early results might provide a secondary driver for the stock.

For now, the clock is ticking on the 80th event. The company has pledged to announce the milestone immediately once it arrives, but no fixed date exists. Until that trigger is pulled and the data unblinded, Sellas remains a binary bet priced for an answer it does not yet have — trading not on evidence, but on the weight of two missing numbers.